The eye disease treatment company, backed by the biotech corporate venturing division of AstraZeneca, takes total funds raised to an estimated $169.6m.
Eye disease drug developer Inotek Pharmaceuticals, backed by corporate venturing unit MedImmune Ventures, has raised $23.6m in its latest funding round.
A Securities and Exchange Commission filing said the company had raised the sum but it was unclear which firms participated in the latest round.
MedImmune Ventures, the corporate venturing division of Anglo-Swedish pharmaceuticals company AstraZeneca, backed last year’s series D round, which raised $18m. Devon Park Bioventures, a US-based venture capital (VC) firm, led last year’s round as a new…
